Linked Life Data

11948467

Source:http://linkedlifedata.com/resource/pubmed/id/11948467

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2002-4-11
pubmed:abstractText
To assess the frequency and prognostic impact of Ep-CAM and Her-2/neu overexpression in patients with breast cancer and to determine its relationship with other prognostic markers, 205 breast cancer patients with a median follow-up of 10.8 years were enrolled in this retrospective study. Overexpression of Ep-CAM and Her-2/neu in tumor tissue samples was assessed by immunohistochemistry. Tumors presenting a Her-2/neu 2+ staining were additionally analyzed by FISH to exclude false positive results. Ep-CAM and Her-2/neu overexpression was found in 35.6% and 19.5% of the tumor samples, respectively. Both Ep-CAM and Her-2/neu overexpression were predictive for poor disease-free (DFS) and disease-related overall survival (DROS). Concurrent Ep-CAM and Her-2/neu overexpression was present in 13.2% of tumor specimens and had an additive negative impact on DFS and DROS. This minority of patients had a median time to relapse of only 34 months, whereas the median time to relapse was not reached in the patient population without Her-2/neu and Ep-CAM overexpression. By multivariate analysis Ep-CAM overexpression proved to be an indicator of poor prognosis, independent of tumor size, histologic grade, hormone receptor expression and Her-2/neu overexpression. In conclusion, overexpression of Ep-CAM and Her-2/neu complement each other as predictors for poor prognosis in patients with invasive breast cancer. Determination of these tumor markers should help in assigning breast cancer patients to 1 of 3 distinct risk categories.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0020-7136
pubmed:author
pubmed:copyrightInfo
Copyright 2002 Wiley-Liss, Inc.
pubmed:issnType
Print
pubmed:day
20
pubmed:volume
98
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
883-8
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:11948467-Adult, pubmed-meshheading:11948467-Aged, pubmed-meshheading:11948467-Aged, 80 and over, pubmed-meshheading:11948467-Antigens, CD3, pubmed-meshheading:11948467-Antigens, Neoplasm, pubmed-meshheading:11948467-Breast Neoplasms, pubmed-meshheading:11948467-Carcinoma, Ductal, Breast, pubmed-meshheading:11948467-Carcinoma, Lobular, pubmed-meshheading:11948467-Cell Adhesion Molecules, pubmed-meshheading:11948467-Disease-Free Survival, pubmed-meshheading:11948467-Female, pubmed-meshheading:11948467-Humans, pubmed-meshheading:11948467-Immunoenzyme Techniques, pubmed-meshheading:11948467-In Situ Hybridization, Fluorescence, pubmed-meshheading:11948467-Middle Aged, pubmed-meshheading:11948467-Neoplasm Invasiveness, pubmed-meshheading:11948467-Neoplasm Staging, pubmed-meshheading:11948467-Prognosis, pubmed-meshheading:11948467-Receptor, erbB-2, pubmed-meshheading:11948467-Receptors, Estrogen, pubmed-meshheading:11948467-Receptors, Progesterone, pubmed-meshheading:11948467-Retrospective Studies, pubmed-meshheading:11948467-Tumor Markers, Biological
pubmed:year
2002
pubmed:articleTitle
Prognostic significance of Ep-CAM AND Her-2/neu overexpression in invasive breast cancer.
pubmed:affiliation
Division of Hematology and Oncology, University of Innsbruck, Innsbruck, Austria.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't